Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Griffith L, Kim SW, Janssan A, Di Giovanni G, Pisaniello AD, Scherer DJ, Psaltis PJ, Butters J. Nicholls SJ, et al. Among authors: keyserling c. JAMA Cardiol. 2018 Sep 1;3(9):815-822. doi: 10.1001/jamacardio.2018.2121. JAMA Cardiol. 2018. PMID: 30046828 Free PMC article. Clinical Trial.
Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.
Andrews J, Janssan A, Nguyen T, Pisaniello AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Andrews J, et al. Among authors: keyserling c. Cardiovasc Diagn Ther. 2017 Feb;7(1):45-51. doi: 10.21037/cdt.2017.01.01. Cardiovasc Diagn Ther. 2017. PMID: 28164012 Free PMC article.
Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden.
Kataoka Y, Andrews J, Duong M, Nguyen T, Schwarz N, Fendler J, Puri R, Butters J, Keyserling C, Paolini JF, Dasseux JL, Nicholls SJ. Kataoka Y, et al. Among authors: keyserling c. Cardiovasc Diagn Ther. 2017 Jun;7(3):252-263. doi: 10.21037/cdt.2017.02.01. Cardiovasc Diagn Ther. 2017. PMID: 28567351 Free PMC article.
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA.
Kootte RS, Smits LP, van der Valk FM, Dasseux JL, Keyserling CH, Barbaras R, Paolini JF, Santos RD, van Dijk TH, Dallinga-van Thie GM, Nederveen AJ, Mulder WM, Hovingh GK, Kastelein JP, Groen AK, Stroes E. Kootte RS, et al. J Lipid Res. 2015 Mar;56(3):703-712. doi: 10.1194/jlr.M055665. Epub 2015 Jan 5. J Lipid Res. 2015. PMID: 25561459 Free PMC article. Clinical Trial.
The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study.
Hovingh GK, Smits LP, Stefanutti C, Soran H, Kwok S, de Graaf J, Gaudet D, Keyserling CH, Klepp H, Frick J, Paolini JF, Dasseux JL, Kastelein JJ, Stroes ES. Hovingh GK, et al. Among authors: keyserling ch. Am Heart J. 2015 May;169(5):736-742.e1. doi: 10.1016/j.ahj.2015.01.008. Epub 2015 Jan 28. Am Heart J. 2015. PMID: 25965722 Clinical Trial.
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels.
Zheng KH, Kaiser Y, van Olden CC, Santos RD, Dasseux JL, Genest J, Gaudet D, Westerink J, Keyserling C, Verberne HJ, Leitersdorf E, Hegele RA, Descamps OS, Hopkins P, Nederveen AJ, Stroes ESG. Zheng KH, et al. Among authors: keyserling c. Atherosclerosis. 2020 Oct;311:13-19. doi: 10.1016/j.atherosclerosis.2020.08.004. Epub 2020 Aug 29. Atherosclerosis. 2020. PMID: 32919280 Free article. Clinical Trial.
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.
Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD; Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators. Tardif JC, et al. Among authors: keyserling c. Eur Heart J. 2014 Dec 7;35(46):3277-86. doi: 10.1093/eurheartj/ehu171. Epub 2014 Apr 29. Eur Heart J. 2014. PMID: 24780501 Free PMC article. Clinical Trial.
HDL mimetic CER-001 targets atherosclerotic plaques in patients.
Zheng KH, van der Valk FM, Smits LP, Sandberg M, Dasseux JL, Baron R, Barbaras R, Keyserling C, Coolen BF, Nederveen AJ, Verberne HJ, Nell TE, Vugts DJ, Duivenvoorden R, Fayad ZA, Mulder WJM, van Dongen GAMS, Stroes ESG. Zheng KH, et al. Among authors: keyserling c. Atherosclerosis. 2016 Aug;251:381-388. doi: 10.1016/j.atherosclerosis.2016.05.038. Epub 2016 May 27. Atherosclerosis. 2016. PMID: 27263077 Free article.
CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
Tardy C, Goffinet M, Boubekeur N, Ackermann R, Sy G, Bluteau A, Cholez G, Keyserling C, Lalwani N, Paolini JF, Dasseux JL, Barbaras R, Baron R. Tardy C, et al. Among authors: keyserling c. Atherosclerosis. 2014 Jan;232(1):110-8. doi: 10.1016/j.atherosclerosis.2013.10.018. Epub 2013 Nov 8. Atherosclerosis. 2014. PMID: 24401224
31 results